PAUL CAPITAL
PAUL CAPITAL is a Series C+, buyout and secondary fund in the US, Latin America, Europe, Middle East, Africa, Asia, Australia and Global investing in software, pharmaceuticals, biotechnology and healthcare-tech.
Not currently making new investments (as of June 11, 2026).
- Stages
- Series C+, buyout, secondary
- Sectors
- software, pharmaceuticals, biotechnology, healthcare-tech
- Invests in
- US-wide, Latin America, Europe, Middle East, Africa, Asia, Australia, Global
- Actively investing
- No
- Founded
- 1991
- Assets under management
- $520.9M
- Website
- paulcap.com
Check size not disclosed
Thesis
The firm has also engaged in fund-of-funds activities, investing in venture capital and middle-market buyout funds, and previously had a healthcare direct investment business focused on royalty and revenue interests. Its geographic scope has been global, with offices and representatives across North America, Latin America, Europe, the Middle East, Africa, Asia, and Australia. Specific funds like Paul Capital Partners IX (2007 vintage) and X targeted software, pharmaceuticals, and biotechnology sectors in North America and Western Europe. The firm managed significant assets, with AUM reported at $520,903,769 as of December 31, 2025. While specific check sizes are not detailed, transactions in the secondary market are substantial. The firm has undergone structural changes, with its funds-of-funds unit spinning out as Top Tier Capital Partners in 2011, and some sources indicate potential wind-down or exploration of strategic buyers.
Common questions
Does PAUL CAPITAL invest at the Series C+ stage?
Yes. PAUL CAPITAL lists Series C+, buyout and secondary among the stages it invests in.
Where does PAUL CAPITAL invest?
PAUL CAPITAL invests in the US, Latin America, Europe, Middle East, Africa, Asia, Australia and Global.